An open, randomised trial to compare desensitisation with rechallenge when restarting co-trimoxazole as prophylaxis against pneumocystis carinii pneumonia (PCP) in patients with Human Immunodeficiency Virus (HIV) infection and a history of mild to moderate cutaneous and/or febrile reactions to co-trimoxazole

INTERVENTION: Co‐trimoxazole/desensitisation/direct rechallenge CONDITION: HIV, Acquired Immunodeficiency Syndrome (AIDS) ; Infections and Infestations ; Human immunodeficiency virus (HIV) PRIMARY OUTCOME: Proportion of patients still taking co‐trimoxazole four and 24 weeks after trial entry SECONDARY OUTCOME: Not provided at time of registration INCLUSION CRITERIA: 1. Past or current severe reactions to co‐trimoxazole 2. Other severe skin conditions 3. Creatinine above 250 micromoles/l, Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) above five times local limit 4. Haemoglobin below 10.5 g/dl, neutrophils below 0.75, platelets below 50